NEFL and amyotrophic lateral sclerosis: The availability of an accessible and quantitative marker of neuro-axonal damage whose concentrations remain uniform in the same patient throughout the progression of the established disease is an optimal hypothetical starting scenario for the use of NfL as a biomarker of response in ALS.